Triplet Therapeutics
As Senior Director of Molecular & Cell Biology at Triplet Therapeutics, Inc., Eva Asp leads a team of scientists to develop assays to screen therapeutics to treat triplet repeat disorders. Prior to joining Triplet, Eva worked at Proclara Biosciences where she developed therapeutics to treat neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease. Eva holds a M.S in Genetics and a Ph.D. in molecular biology from Gothenburg University, Sweden.
This person is not in any offices
Triplet Therapeutics
Triplet Therapeutics is a biotechnology company developing transformational treatments for patients with repeat expansion disorders (REDs) -- a group of more than 50 known genetic diseases including Huntington’s disease, myotonic dystrophy, spinocerebellar ataxias, fragile X syndrome, and familial amyotrophic lateral sclerosis (ALS) -- leveraging insights from patient genetics. Triplet designs and develops potential therapeutics for REDs using its proprietary thRED Engine, which enables the Company to develop a single oligonucleotide targeting the DNA Damage Response (DDR) pathway to potentially treat multiple REDs. Triplet is backed by investments from Atlas Venture, MPM Capital and Pfizer Ventures, along with Invus, Partners Innovation Fund and Alexandria Venture Investments.